Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trial Transparency Gets A Boost With J&J Agreement, IOM Report

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's device and diagnostic clinical trial data is now available to independent researchers via Yale University’s Open Data Access (YODA) Project, announced the same day as an Institute of Medicine report mapping out strategies for clinical trial data-sharing.

Advertisement

Related Content

TCT 2016: Researchers Argue For More Medtech Data Sharing
Journal Editors Press For More Disclosure Of Underlying Trial Data
Journal Editors Press For More Disclosure Of Underlying Trial Data
Researchers Debate Costs Of Clinical Trial Data Sharing At IOM Gathering
J&J Works Toward Device Data-Sharing Agreement Following Pharma Plan
J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group
Infuse Open-Access Project A Model For The Future? Medtronic Thinks So

Topics

Advertisement
UsernamePublicRestriction

Register

MT034062

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel